Lexicon to face FDA AdComm for Zynquista approval in diabetes and CKD
A FDA advisory committee (AdComm) is set to evaluate Lexicon’s Zynquista as an adjunct therapy for type 1 diabetes and chronic kidney disease.
Therapy Area
Leo Pharma’s Timber bet falls flat following Phase III failure
FDA declines to approve Regeneron’s linvoseltamab amid manufacturing issues
Aadi axes 80% of staff after registrational Phase II trial fails
Licensing agreements for innovator GLP1R drugs weigh in with over $6.2bn in 2024
How personalised medicine can revolutionise contraception
NMPA approves AstraZeneca’s Fasenra for severe asthma
Amgen’s Otezla launched for paediatric plaque psoriasis in US
